Pluristem Therapeutics Inc (PSTI)

[FDApproved]

Data collated 12 months post-treatment with PLX-R18 demonstrate that:

1. PLX-R18 was well-tolerated with a favorable safety profile.

2. Patients treated with PLX-R18 showed an increase in all three blood cell types compared to baseline with platelets (p<0.001), hemoglobin (p=0.01) and
neutrophils (p=0.15) levels increasing as early as 1 month following PLX-R18 administration and enduring up to 12 months following treatment


3. Following PLX-R18 treatment, the number of transfused units decreased from a mean monthly number of 5.09 for platelets and 2.91 for red blood cells at baseline to 0.55 for platelets (p=0.045) and 0 for red blood cells (p=0.0005) at 12 months.

4. The observed annual mortality rate following PLX-R18 administration was 18% compared to 29% in a cohort of allogeneic HCT recipients with incomplete
hematopoietic recovery, obtained from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, representing a similar patient
population.